To evaluate crizotinib-induced hepatotoxicity in mice and investigate the role of cell cycle arrest mediated by LOC440416lncRNA during liver injury, furthermore, to provide experiment evidence for screening available hepar protector and expending the clinical application of crizotinib. The levels of blood serum ALT, AST, LDH were detected using ICR mouse model. Liver samples of mouse fixed were stained with hematoxylin and eosin for histopathological analysis. The cell inhibition rate of primary hepatocytes was detected by MTT assay.Cell cyclin distribution was detected by flow cytometry(FCM) and the expressions of cell cycle protein cyclinB1 and CDK1 were detected with Westblot after mouse primary hepatocytes were treated with 2.5 μM, 5μM, 10 μM crizotinib for 48h. Apoptosis was evaluated by DAPI staining and PI staining for flow cytometry and the expressions of cell apoptosis protein c-PARP and c-caspase-3 were detected with Westblot. LncRNAs regulating hepar cell cycle arrest were screened using Microarray Chip technique after primary hepatocytes were treated with 5μM crizotinib for 24h. The expressions of cell cyclin protein cyclin B1 and CDK1 were tested with Westblot, after siRNA gene silencing technology was used to knock down LOC440416lncRNA. The levels of blood serum ALT, AST, LDH elevated significantly in mice after crizotinib treatment. Slices of liver by HE staining for analysis showed cellular swelling of hepatocytes, nucleolus staining deepened and karyokinesis phenomenon with inflammatory cell infiltrate. In vitro, MTT assay showed crizotinib-induced hepatotoxicity in mouse primary hepatocytes presented dose-dependented and IC50 value was 4.6μM. DAPI staining exhibited clear chromatin condensation, fragment and apoptotic bodies and FCM showed sub-G1 apoptosis peak was formed after 5μM and10 μM crizotinib treatment. Westblot demonstrated caspase-3 activation and PARP cleavage. All these data revealed that crizotinib-induced hepatotoxicity was through the process of apoptosis. FCM showed the population of G2/M phase elevated, these of G0/G1 phase decreased and G2/M arrested while the concentration of crizotinib was increased. Reduced protein levels of Cyclin B1 and increased protein level of CDK1 were also observed with Westblot. After crizotinib treatment, sixteen elevated or decreased lncRNAs were found more than ten times separately by terms of Microarray Chip technique. LOC440416lncRNA regulating cell cycle arrest was screened by Real-time PCR. The restoration of reduced Cyclin B1, increased CDK1 expressions, even if hepatocytes were treated with crizotinib, after siRNA gene silencing technology was used to knock down LOC440416lncRNA. Crizotinib-induced hepatotoxicity was demonstrated by experiment in vivo and in vitro. Cell cyclin G2/M check point arrest accompanied with decreased expression of cyclin B1 protein and increased expression CDK1, mediated by LOC440416 lncRNA, could be the possible mechanism.
Read full abstract